Saturday, November 21, 2026
Financial News
Sep 30, 2026, 2:32 PMPharmaceuticals

Eli Lilly’s Zepbound and Amylin Combination Delivers Up to 23% Weight Loss

Eli Lilly’s experimental amylin drug, added to Zepbound, helped people lose up to 23% of weight but increased side effects; details remain very limited.

A balance scale weighs a shrinking mass against red thorns, symbolizing greater weight loss and more side effects.
Listen to this briefingAudio briefing

Summary

MarketWatch reported on September 30, 2026, that adding Eli Lilly’s experimental amylin drug to Zepbound helped people lose up to 23% of their weight, although the combination produced more side effects.

Lilly is studying whether the candidate can support weight loss and diabetes management similarly to GLP-1 therapies. Only a short feed summary was available, with no drug name, trial design, participant count, treatment duration, adverse-event rates or next milestones disclosed.

Positives

  • Up to 23% weight loss was reported when Eli Lilly’s experimental amylin candidate was added to Zepbound.
  • Eli Lilly is evaluating the candidate for both weight loss and diabetes management.
  • The amylin program targets benefits similar to those associated with GLP-1 therapies.

Risks & concerns

  • More side effects occurred when the experimental amylin drug was combined with Zepbound.
  • The amylin candidate remains experimental, and the available summary provided no development or regulatory timeline.
  • The limited feed omitted trial size, duration, adverse-event frequencies and other data needed to assess the result fully.
Primary sourceMarketWatch.com - Top Storieshttps://www.marketwatch.com/story/adding-lillys-new-drug-to-zepbound-helped-people-lose-up-to-23-of-their-weight-but-there-were-more-side-effects-b7b7c6c0?mod=mw_rss_topstories
Read full article
Editorial note: Financial News summarizes and analyzes third-party reporting and public filings. The source link is the authoritative document. This page does not reproduce the full source text and is not investment advice.

More From The Wire

A vaccine vial lighthouse illuminates cancer cells and a neural web amid a political storm. PharmaceuticalsNov 12

Drugmakers Bet Billions on Vaccines as Moderna and Merck Data Show Promise

A medicine injector casts a dark shadow across an eye, symbolizing possible GLP-1-related vision loss. PharmaceuticalsNov 9

Ozempic, Zepbound and GLP-1 Drugs Linked to Possible Vision Loss Risk

A capsule-shaped buoy lifts a sagging financial line, reflecting Wegovy's support for Novo Nordisk's outlook. PharmaceuticalsNov 4

Novo Nordisk Stock Jumps as Wegovy Pill Uptake Lifts Guidance